Phase I and Expansion Study of Eprenetapopt (APR-246) in Combination with Venetoclax (VEN) and Azacitidine (AZA) in TP53-Mutant Acute Myeloid Leukemia (AML)
Blood (2021) 138 (Supplement 1): 3409.
Currently there are no citedby results. Try again later.
